Search the Newsreel

Daily Brief China: SHEIN Global Holdings, Lenovo, Modern Dental Group, Suzhou Zelgen Biopharmaceuticals, Hangzhou CIEC Group and more

Why Immunovant (IMVT) Is Up 5.2% After Wider Q1 Loss, Moderna Cash, And Pivotal Data Hype

Immunovant (IMVT) saw its stock rise by 5.2% despite reporting a wider net loss in Q1 2026, reaching US$153.22 million. This positive market reaction is attributed to the anticipation of multiple upcoming pivotal data readouts for its IMVT-1402 drug and a significant upfront payment …

Moderna Secures U.S. mRNA Flu Vaccine Approval, Revenue Gains Not Expected Before 2027

Clifford Modern Living Sets August Board Meeting to Review Interim Results

US Stock Futures Flat After S&P500, Dow End At Record Highs On Strong Earnings, Easing Geopolitical Concerns — PLTR, AZN, CMG, MRNA In Focus

Modern Chinese Medicine Group Sets August Board Meeting for Interim Results and Dividend Review

Modern Healthcare Technology Details Higher Audit Fee in KPMG Reappointment Plan

Modern Dental Group Forecasts Sharp Interim Profit Growth on Overseas Strength

MRNA Stock Closes Down On Profit-Taking Following 20% Weekly Rally And Hantavirus Buzz

Capital World Investors reports 5.6% Moderna (MRNA) stake in Schedule 13G filing

Capital World Investors, an investment management entity, has reported a 5.6% beneficial ownership stake in Moderna, Inc. (MRNA) through a Schedule 13G filing. This represents 22,276,996 shares out of 396,786,259 outstanding shares, with the firm holding sole voting power over 22,264,639 shares and sole …

Projeções de Resultados: Moderna Inc (MRNA) — LPA e Crescimento de Receita

Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?

A landmark legal settlement in the biotech sector recently reshaped the financial trajectories of two key mRNA technology players: Arbutus Biopharma Corporation (NASDAQ:ABUS) and Moderna, Inc. (NASDAQ:MRNA). The resolution of their global patent infringement litigation over lipid nanoparticle (LNP) delivery technology provided Arbutus with …

Moderna: I'm Still On The Sidelines, But Here's What Would Change My Mind (NASDAQ:MRNA)

Moderna faces significant valuation challenges, requiring flawless execution and rapid margin expansion from its late-stage pipeline to justify its $20B+ market capitalization. While the FDA approval of mFLUSIVA is a milestone, its projected $1 billion peak sales are a best-case scenario given market competition …

China Modern Dairy Sets Board Meeting for Interim Results and Dividend Plan

Moderna, Inc. $MRNA Shares Acquired by Contravisory Investment Management Inc.

Contravisory Investment Management Inc. significantly increased its stake in Moderna (NASDAQ: MRNA) by 1,387.6% in Q2, acquiring an additional 22,590 shares, bringing its total to 24,218 shares valued at $1.696 million. This comes as institutional investors now own 75.33% of Moderna's stock. The company …

Modern Dairy (1117.HK): H1 Profit Surprise + Acquisition Completed; Second-Half Outlook Points to a Cyclical Reversal

Moderna (MRNA) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Friday, July 31, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Chief Executive Officer - Stphane BancelPresident - Stephen HogeChief Financial Officer - James MockChief Development Officer - David Berman TAKEAWAYS Total Revenue -- $145 million, representing 2% growth …

Rule 10b5-1 plan drives Moderna, Inc. (NASDAQ: MRNA) CEO stock sales

Moderna CEO Stéphane Bancel exercised stock options for 751,715 shares and subsequently sold 499,246 shares under a pre-arranged Rule 10b5-1 trading plan. The sales, totaling approximately $28.72 million, were conducted between $55.58 and $59.34 per share to cover exercise costs, withholding taxes, and transaction …

Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones

Moderna's Q2 2026 earnings call focused on two main priorities: maintaining revenue growth while cutting costs and advancing late-stage pipeline programs. The company reported revenues of $145 million, exceeding estimates, and a GAAP loss of $1.97 per share, matching expectations. Moderna reiterated its target …

The flu shot finally gets an upgrade

Moderna's new mRNA flu vaccine has been approved by the FDA, representing a significant public health advancement. This mRNA vaccine is expected to offer better protection against the flu compared to traditional vaccines because it can be produced faster, better addressing the rapid mutation …

The mRNA technology behind Moderna’s Covid vaccine reaches the flu

The FDA has approved Moderna's mFlusiva, the first mRNA-based flu vaccine for adults 50 and older, similar to their Covid-19 vaccine. This new vaccine offers a faster manufacturing process for annual flu shot updates and aims to enhance protection for vulnerable populations, despite causing …

What Moderna is and how it built its mRNA vaccine platform

Moderna, founded in 2010, is a Cambridge-based biotechnology company that pioneered mRNA medicine, becoming a global pharmaceutical player through its widely distributed Covid-19 vaccine. Its core thesis is that mRNA technology can be quickly adapted to target a wide range of diseases, leading to …

Moderna’s flu shot crosses FDA finish line, bouncing back from regulatory roadblock

Moderna's mRNA-based flu vaccine, mFLUVISA, has received FDA approval for seasonal influenza prevention in adults 50-64 (traditional approval) and 65+ (accelerated approval). This approval follows an initial refusal-to-file letter from the FDA in February, which was later rescinded after industry criticism. The vaccine is …

Moderna, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:MRNA) 2026-08-06

Image source: The Motley Fool. DATE Friday, July 31, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Chief Executive Officer - Stphane BancelPresident - Stephen HogeChief Financial Officer - James MockChief Development Officer - David Berman TAKEAWAYS Total Revenue -- $145 million, representing 2% growth …

Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA

Moderna has received U.S. FDA approval for its influenza vaccine, mFLUSIVA (mRNA-1010), for use in adults 50 years and older. This marks Moderna's fifth approved product globally and fourth FDA-approved product, making it the first mRNA-based flu vaccine. The company anticipates mFLUSIVA will be …

Moderna secures FDA approval for its first mRNA influenza vaccine

Moderna has received FDA approval for mFLUSIVA, its first mRNA-based influenza vaccine, for adults aged 50 and over. This marks Moderna's fourth FDA-approved product and its fifth authorized product worldwide, with distribution expected to begin soon for the 2026-2027 respiratory virus season. The approval …

FDA Approves First mRNA Flu Vaccine in Win for Moderna After Arduous Process

The FDA has approved Moderna's mRNA-based flu vaccine, mFlusiva, for adults aged 50 and older. This marks the first mRNA flu shot to receive approval, following a challenging review process. The vaccine, which uses the same technology as Moderna's COVID-19 shots, is expected to …

Moderna’s mRNA Flu Shot Wins US Approval in FDA Turnaround

Moderna Inc. has received US regulatory approval for its mRNA-based flu vaccine. The vaccine is approved for adults aged 50 and over, with traditional approval for ages 50-64 and accelerated approval for those 65 and older. This marks a significant victory for Moderna, especially …

US FDA approves first mRNA flu shot from Moderna

The U.S. Food and Drug Administration has approved Moderna's mFlusiva, making it the first mRNA-based vaccine for seasonal flu. The shot is approved for individuals aged 50 and older, with a traditional approval for ages 50-64 and an accelerated approval for those 65 and …

Moderna Appeals District Court Infringement Judgment over COVID Vaccines

Moderna has appealed a District Court judgment concerning patent infringement related to its COVID-19 vaccines, arguing that the U.S. government, not Moderna, should bear the liability under 28 U.S.C. § 1498(a). The company claims that its Spikemax® vaccine was developed and distributed "for the …

Moderna, Inc. SEC Filing (Aug 5, 2026)

This article reports on a Form 144 SEC filing by Moderna, Inc. (MRNA) on August 5, 2026. The filing indicates a proposed sale of 499,246 shares of common stock with an aggregate market value of $28,956,268.00, resulting from a stock option exercise by an …

Moderna Advances Ebola Vaccine Into Human Testing

Moderna has initiated a Phase 1 clinical trial for its investigational Ebola vaccine, mRNA-1469, which targets the Bundibugyo ebolavirus and has no currently licensed vaccines. This advancement follows a collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI), which committed up to $50 million. …

Moderna, Inc. $MRNA Shares Bought by Quantinno Capital Management LP

Quantinno Capital Management LP increased its stake in Moderna (MRNA) by 74.7% during the first quarter, now owning 168,077 shares worth approximately $8.5 million. Despite beating quarterly revenue and EPS expectations, Moderna remains unprofitable, and analysts maintain a "Reduce" rating with an average price …